CVS Health (CVS) director receives 1,447 deferred stock units as retainer

Rhea-AI Filing Summary

CVS Health Corp director John E. Gallina received 1,447.5039 deferred stock units on May 14, 2026. The units were issued as a semi-annual retainer under the company’s non-employee director compensation policy, valued at $97.15 per unit, and each unit will convert into one share of common stock at a future time he elects.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gallina John E

Role null

Type	Security	Shares	Price	Value
Grant/Award	Deferred Stock Units	1,447.504	$97.15	$141K

Holdings After Transaction: Deferred Stock Units — 1,447.504 shares (Direct, null)

Footnotes (1)

1. Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan. Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.

Key Figures

Deferred stock units granted: 1,447.5039 units Unit valuation: $97.15 per unit Units following transaction: 1,447.5039 units +1 more

4 metrics

Deferred stock units granted 1,447.5039 units Grant to director John E. Gallina on May 14, 2026

Unit valuation $97.15 per unit Value used for semi-annual retainer under compensation plan

Units following transaction 1,447.5039 units Total deferred stock units held after this award

Underlying common shares 1,447.5039 shares Each deferred unit converts into one common share

Key Terms

Deferred Stock Units, non-employee director compensation policy, 2017 Incentive Compensation Plan, semi-annual retainer

4 terms

Deferred Stock Units financial

"Consists of deferred stock units issued for deferral of a semi-annual retainer"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

non-employee director compensation policy financial

"in connection with the Issuer's non-employee director compensation policy"

2017 Incentive Compensation Plan financial

"pursuant to the Issuer's 2017 Incentive Compensation Plan"

semi-annual retainer financial

"issued for deferral of a semi-annual retainer in connection with the policy"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gallina John E

(Last) (First) (Middle)

ONE CVS DRIVE

(Street)

WOONSOCKET RHODE ISLAND 02895

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CVS HEALTH Corp [ CVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	$0	05/14/2026		A(1)		1,447.5039		(2)	(2)	Common Stock	1,447.5039	$97.15	1,447.5039	D

Explanation of Responses:

1. Consists of deferred stock units issued for deferral of a semi-annual retainer in connection with the Issuer's non-employee director compensation policy, valued at the market price, pursuant to the Issuer's 2017 Incentive Compensation Plan.

2. Consists of deferred stock units, each to be converted into one share of common stock and issued in the future, as elected by the Reporting Person.

	/s/ John E. Gallina	05/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did CVS (CVS) director John E. Gallina report in this Form 4?

John E. Gallina reported receiving 1,447.5039 deferred stock units from CVS Health Corp. These units were issued as part of his semi-annual director retainer and represent equity-based compensation rather than an open-market stock purchase or sale.

How many CVS deferred stock units were granted to John E. Gallina?

Gallina was granted 1,447.5039 deferred stock units. These units are tied to CVS Health common stock and were issued as compensation under the company’s non-employee director policy for a semi-annual retainer, not through a market transaction.

At what value were John E. Gallina’s CVS deferred stock units recorded?

The deferred stock units were valued at $97.15 per unit. This valuation reflects the market price used under CVS Health’s 2017 Incentive Compensation Plan when issuing equity compensation to non-employee directors as part of their regular retainer.

What does it mean that CVS granted deferred stock units to a director?

Deferred stock units are a form of equity compensation that track CVS Health’s common stock. Each unit will convert into one share of common stock and be issued in the future, at a time elected by director John E. Gallina under plan rules.

Were John E. Gallina’s CVS transactions a stock purchase or sale?

No, the Form 4 shows an acquisition coded as a grant or award, not a market trade. The 1,447.5039 deferred stock units were issued as compensation, so this is not an open-market buy or sell by the director.